Company profile
VERRICA PHARMACEUTICALS INC.
NASDAQ:VRCABiotechnology: Pharmaceutical Preparations
Drug pipeline (1)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| YCANTH | approved | $5.1MQ2 2026 | 0 | — |
Revenue is the latest quarter the company reported for that product, from SEC filings; a fourth quarter is the year less nine months when no filing states one. Trial counts are of the product's ingredients, deduplicated by trial, so products sharing an ingredient share trials.
Clinical trials (1)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT05188729 | phase2 | completed | 2022-02-01 | 2024-04-15 | Verrica Pharmaceuticals Inc. | Open-Label Proof of Concept Study of VP-315 in Basal Cell Carcinoma |
FDA applications (1)
| Application | Approved | Type | Applicant | Products | ||||
|---|---|---|---|---|---|---|---|---|
| NDA 212905 | 2023-07-21 | NDA | VERRICA PHARMACEUTICALS INC | |||||
Loading… | ||||||||